-$0.11 Earnings Per Share Expected for vTv Therapeutics Inc (NASDAQ:VTVT) This Quarter

Analysts expect vTv Therapeutics Inc (NASDAQ:VTVT) to post ($0.11) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for vTv Therapeutics’ earnings, with estimates ranging from ($0.16) to ($0.05). vTv Therapeutics reported earnings per share of ($0.29) during the same quarter last year, which would indicate a positive year-over-year growth rate of 62.1%. The company is scheduled to announce its next quarterly earnings results on Friday, August 2nd.

On average, analysts expect that vTv Therapeutics will report full year earnings of ($0.59) per share for the current fiscal year. For the next fiscal year, analysts anticipate that the firm will report earnings of ($0.40) per share, with EPS estimates ranging from ($0.60) to ($0.19). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for vTv Therapeutics.

vTv Therapeutics (NASDAQ:VTVT) last issued its earnings results on Wednesday, May 1st. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter. The business had revenue of $0.92 million for the quarter.

A number of equities analysts have commented on the stock. ValuEngine lowered shares of vTv Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, June 3rd. HC Wainwright began coverage on shares of vTv Therapeutics in a research report on Thursday, May 30th. They set a “buy” rating and a $5.00 target price on the stock. Northland Securities set a $3.00 target price on shares of vTv Therapeutics and gave the stock a “hold” rating in a research report on Monday, March 18th. Finally, Zacks Investment Research lowered shares of vTv Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, May 2nd.

VTVT traded down $0.04 during trading on Friday, hitting $1.39. The stock had a trading volume of 112,424 shares, compared to its average volume of 1,113,337. The company has a market capitalization of $71.96 million, a PE ratio of -2.03 and a beta of -3.70. vTv Therapeutics has a 12 month low of $0.68 and a 12 month high of $6.09.

In related news, major shareholder Ronald O. Perelman bought 1,358,698 shares of vTv Therapeutics stock in a transaction dated Wednesday, May 15th. The shares were bought at an average cost of $1.84 per share, for a total transaction of $2,500,004.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.70% of the stock is currently owned by corporate insiders.

Several hedge funds have recently made changes to their positions in the company. Sabby Management LLC acquired a new position in shares of vTv Therapeutics during the first quarter worth approximately $382,000. D. E. Shaw & Co. Inc. bought a new stake in shares of vTv Therapeutics during the fourth quarter worth approximately $186,000. Barclays PLC raised its stake in shares of vTv Therapeutics by 366.7% during the fourth quarter. Barclays PLC now owns 28,000 shares of the biotechnology company’s stock worth $74,000 after buying an additional 22,000 shares during the last quarter. Morgan Stanley raised its stake in shares of vTv Therapeutics by 147,061.5% during the first quarter. Morgan Stanley now owns 19,131 shares of the biotechnology company’s stock worth $33,000 after buying an additional 19,118 shares during the last quarter. Finally, Wedbush Securities Inc. bought a new stake in shares of vTv Therapeutics during the first quarter worth approximately $30,000. Institutional investors own 3.94% of the company’s stock.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase II/III clinical trials for the treatment of mild Alzheimer's disease.

Featured Story: What does earnings per share mean?

Get a free copy of the Zacks research report on vTv Therapeutics (VTVT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.